# ‚öîÔ∏è TRIAL INTELLIGENCE REPORT: NCT06394804 ‚öîÔ∏è

**Trial Name**: A Study of Avutometinib, Defactinib, and Letrozole in People...  
**Patient**: AK (ID: ayesha_001)  
**Generated**: 2025-11-15T21:55:51.029882  
**Generated By**: Zo (Lead Commander)  
**Match Tier**: TOP_TIER  
**Composite Score**: 0.97/1.00  
**Eligibility Probability**: ~100%

**ClinicalTrials.gov**: https://clinicaltrials.gov/study/NCT06394804

---

## üî• WHY THIS MATTERS FOR AYESHA - CRITICAL ANALYSIS

**Status**: RECRUITING  
**Phase**: N/A  
**Sponsor**: Not specified

### ‚úÖ PIPELINE ASSESSMENT:

‚úÖ Status: RECRUITING
‚úÖ Ovarian cancer trial match
‚úÖ No stage restriction (assume eligible)
- ‚úÖ INTERVENTIONAL treatment trial
- ‚úÖ 7 NYC metro location(s)
- ‚ö†Ô∏è Eligibility: ~100% (pending biomarkers)

**Semantic Similarity**: 0.000 (vector search match)

---

## üß¨ ELIGIBILITY ASSESSMENT FOR AYESHA

| Criterion | Ayesha's Status | Match | Action Required |
|-----------|-----------------|-------|-----------------|
| Stage IV epithelial ovarian | Stage IVB High-Grade Serous Ovarian Carcinoma (HGSOC) | ‚úÖ PASS | None |
| BRCA wildtype | Germline negative | ‚úÖ PASS | None |
| HER2 Status | UNKNOWN | ‚ö†Ô∏è GATE | HER2 IHC (3-5 days) |
| HRD Status | UNKNOWN | ‚ö†Ô∏è PENDING | MyChoice CDx (7-10 days) |
| Treatment Line | first-line | ‚úÖ PASS | None |
| Tissue Available | True | ‚úÖ PASS | None |
| Performance Status | ECOG 1 | ‚úÖ PASS | None |
| Geographic Access | NYC Metro | ‚úÖ PASS | None |

**Probability Ayesha Is Eligible**: ~100%  
**Calculation**: No specific restrictions (100% eligible)

---

## üéØ WHY THIS TRIAL IS A GOOD FIT FOR AYESHA (LLM Analysis)

### **Clinical Analysis: Trial NCT06394804 for AK**

**To:** AK's Clinical Care Team
**From:** Clinical Oncology Expert
**Subject:** Analysis of Trial NCT06394804 for Patient AK (40F, HGSOC)

This analysis concludes that trial NCT06394804 is **not an appropriate clinical option** for Ms. Kiani. The fundamental mismatch between her diagnosis and the trial's target population makes her ineligible and renders the intervention biologically irrelevant to her disease. The priority should be the immediate initiation of the planned standard-of-care (SOC) regimen.

---

#### **1. Drug Mechanism Fit**

There is a fundamental biological mismatch between the trial's intervention and Ms. Kiani's disease.

*   **Histological Incompatibility:** The trial is exclusively for **Low-Grade Serous Ovarian Carcinoma (LGSOC)**. Ms. Kiani has **High-Grade Serous Ovarian Carcinoma (HGSOC)**. These are clinically and molecularly distinct entities. HGSOC is characterized by near-universal TP53 mutations and significant genomic instability, often involving homologous recombination deficiency (HRD). LGSOC, conversely, is a less aggressive, chemo-resistant tumor often driven by mutations in the MAPK pathway (e.g., KRAS, NRAS, BRAF).
*   **Mechanistic Mismatch:** The trial's regimen‚Äîavutometinib (a dual RAF/MEK inhibitor), defactinib (a FAK inhibitor), and letrozole (an aromatase inhibitor)‚Äîis designed to target the MAPK pathway and hormonal signaling common in LGSOC. These are not the primary oncogenic drivers in HGSOC. For Ms. Kiani's BRCA-negative tumor, the most relevant pathways to target are those related to DNA damage repair (addressed by PARP inhibitors post-chemo if HRD-positive) and angiogenesis (addressed by bevacizumab in her planned SOC). The proposed trial drugs have no established efficacy in treatment-naive HGSOC.

#### **2. Location Logistics**

Even if the patient were eligible, the logistics present a significant barrier.

*   **Available Sites:** The listed sites are all Memorial Sloan Kettering (MSK) satellite locations in New Jersey (Basking Ridge, Middletown, Montvale) and outer New York (Commack, Harrison). There are no Manhattan-based sites listed.
*   **Travel Burden:** From her home in East Harlem (ZIP 10029), travel to any of these locations would be arduous, likely requiring 1.5-2.5 hours each way via car or a complex multi-modal public transit journey. For a patient with an ECOG 1 status and symptomatic pleural effusions, this frequent, lengthy travel is clinically inadvisable and would negatively impact her quality of life.
*   **"Limited Protocol Activities":** This designation implies that major assessments, imaging, or complex infusions might still require travel to MSK's main campus in Manhattan, adding another layer of logistical complexity.

#### **3. Risk-Benefit for Ayesha**

The risk-benefit calculation is overwhelmingly negative.

*   **Benefit:** Given the mechanistic mismatch, the anticipated clinical benefit for her HGSOC is negligible to non-existent. Pursuing this trial would mean forgoing a proven, highly effective first-line therapy.
*   **Risk:** Ms. Kiani's large bilateral pleural effusions indicate significant pulmonary compromise. The potential toxicities of the three-drug combination pose a substantial risk:
    *   **Avutometinib (MEK inhibitor):** Known to cause fluid shifts, peripheral edema, and potentially serous retinopathy or cardiomyopathy. Inducing further fluid retention could acutely worsen her pleural effusions and respiratory status.
    *   **Combined Toxicity:** The additive toxicities of a three-drug regimen (rash, fatigue, GI distress) would be challenging for a patient with extensive disease, even with an ECOG 1 status. Exposing her to these risks without a rational expectation of benefit is clinically unwarranted.

#### **4. Comparison to Standard of Care**

The planned SOC is vastly superior to the trial for this patient.

*   **Standard of Care (Carboplatin + Paclitaxel + Bevacizumab):** This is the evidence-based, NCCN-guideline-recommended first-line treatment for Stage IVB HGSOC. It offers a high probability of response, which is urgently needed to control her extensive tumor burden and resolve her life-limiting pleural effusions. Bevacizumab, in particular, is effective at controlling malignant ascites and effusions.
*   **Trial Intervention:** This is an experimental combination for a different disease. Choosing this trial would constitute a deviation from the global standard of care with no scientific justification. The SOC provides the best possible chance for a durable remission and symptom control.

#### **5. Critical Considerations for the Care Team**

1.  **Confirm Ineligibility:** The most critical step is to formally recognize that her HGSOC diagnosis makes her ineligible per the trial's primary inclusion criterion ("Histologically-confirmed LGSOC"). There is no ambiguity on this point.
2.  **Urgency of Treatment:** Ms. Kiani has extensive, symptomatic disease. Delays in initiating effective therapy to explore inappropriate trials would be detrimental to her outcome. The priority must be prompt initiation of carboplatin/paclitaxel/bevacizumab.
3.  **Manage Pulmonary Symptoms:** Concurrently with starting systemic therapy, her large pleural effusions require immediate management, likely via therapeutic thoracentesis, to improve her respiratory function and quality of life.
4.  **Complete Biomarker Testing:** While not relevant for this trial, **expediting HRD testing is critical**. The result will determine her eligibility for maintenance PARP inhibitor therapy following initial chemotherapy, which is a key component of modern HGSOC management and significantly impacts progression-free survival.

---


## üö® CRITICAL DECISION TREE FOR AYESHA

START: Ayesha completes carboplatin + paclitaxel + bevacizumab (L1)
  ‚îÇ
  ‚îú‚îÄ‚Üí Biomarker Testing (if required)
  ‚îÇ    ‚îÇ
  ‚îÇ    ‚îî‚îÄ‚Üí **ELIGIBLE FOR TRIAL!** (pending results)
  ‚îÇ         Probability: ~100%
  ‚îÇ
  ‚îî‚îÄ‚Üí END: Enroll in NCT06394804

---

## üí° STRATEGIC IMPLICATIONS

### Best-Case Scenario:
‚úÖ Ayesha enrolls in NCT06394804
‚úÖ Access to experimental therapy
‚úÖ Close monitoring, expert care
**Probability**: ~100%

### Most Likely Scenario:
Ayesha completes screening and enrolls successfully (pending biomarkers)

### Challenge Scenario:
Screen failure due to biomarker requirements or other eligibility criteria

---

## üìã FULL ELIGIBILITY TEXT

### Eligibility Criteria
* Female patients ‚â• 18 years of age
* Histologically-confirmed LGSOC (ovarian, peritoneal) by tissue biopsy read by pathology at study institution. NOTE: Patients with a prior history of serous borderline tumors without prior systemic (cytotoxic or hormonal) treatment but a new diagnosis of low-grade serous ovarian cancer are eligible.
* Determination that the patient is not a primary surgical candidate by a gynecologic oncologist surgeon; or has undergone an attempted primary debulking with residual RECIST measurable disease.
* Measurable disease according to RECIST 1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension. Each lesion must be ‚â•10mm when measured by CT or MRI. Lymph nodes must be ‚â•15mm by short axis when measured by CT or MRI.
* An Eastern Cooperative Group (ECOG) performance status of ‚â§1. Patients with an ECOG performance status of 2 are permitted on trial if this is deemed to be secondary to cancer but not to other comorbidities.
* Patients with treated brain metastases are eligible if follow-up brain imaging after CNS-directed therapy shows no evidence of progression. Patients with asymptomatic brain metastases that do not require intervention are also eligible.
* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on anti-HCV treatment, they are eligible if they have an undetectable HCV viral load.
* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
* Female patients with reproductive potential agree to use highly effective method of contraceptive during the trial and for 1 month following the last dose of study intervention, unless surgical menopause is conferred. Women of child-bearing potential must have a negative pregnancy test within 14 days prior to commencement of study treatment. Non-hormonal methods of highly effective contraception include:

  * intrauterine device (IUD)
  * bilateral tubal occlusion
  * vasectomized partner
  * sexual abstinence
* Patients must have adequate cardiac function with left ventricular ejection fraction ‚â• 50% by echocardiography (ECHO) or multiple-gated acquisition (MUGA) scan.
* Baseline QTc interval \< 460 ms (Common Terminology Criteria for Adverse Events \[CTCAE\] Grade 1) using Fredericia's QT correction formula. NOTE: This criterion does not apply to patients with a right or left bundle branch block.
* Adequate organ function, defined by the following parameters:

  ¬∞Adequate hematologic function
* Hemoglobin \[Hb\] ‚â• 9.0 g/dL. If a red blood cell transfusion has been administered the Hb must remain stable and ‚â• 9.0 g/dL for at least 1 week prior to first dose of study intervention.
* Platelets ‚â• 100,000/mm\^3
* Absolute neutrophil count \[ANC\] ‚â• 1000/mm\^3

  ¬∞Adequate hepatic function:
* Total bilirubin ‚â§1.5 √ó upper limit of normal \[ULN\] for the institution; patients with Gilbert syndrome may enroll if total bilirubin is \<3.0mg/dL (51 Œºmole/L) upon discussion with MSK PI.
* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ‚â§ 2.5 √ó ULN (or \<5 xULN in patients with liver metastases).

  * Adequate renal function with creatinine clearance rate of ‚â•50 mL/min as calculated by the Cockcroft-Gault formula or serum creatinine of ‚â§ 1.5 x ULN.
  * Creatine phosphokinase (CPK) ‚â§2.5 x ULN. * Patients who are deemed in the opinion of their treating physician to be appropriate candidates for a primary debulking surgery are not eligible for this trial, unless measurable disease remains after a primary cytoreductive surgery.
* Prior systemic anti-cancer therapy for LGSOC or serous borderline disease.
* Major surgery within 4 weeks, minor surgery within 2 weeks, or palliative radiotherapy within 1 week of the first dose of study intervention. Open and close laparotomy and/or laparoscopy will be considered minor surgery.
* Treatment with warfarin. Patients on warfarin for deep vein thrombosis/pulmonary embolism can be converted to low-molecular-weight heparin or direct oral anticoagulants (DOACs).
* Patients with the inability to swallow oral medications or impaired gastrointestinal absorption due to gastrectomy or drainage PEG tube. Patients with diagnosis of bowel obstruction \<3 months from study enrollment will be excluded unless surgically cured or approved by study PI.
* Symptomatic brain metastases requiring steroids or other interventions. Patients with new asymptomatic CNS metastases detected during the screening period must receive radiation therapy and/or surgery for CNS metastases. Following treatment, these patients may then be eligible if all other criteria are met.
* Patients with history of retinal pathology or evidence of visible retinal pathology that is considered a risk factor for RVO, intraocular pressure \> 21 mm Hg as measured by tonometry, or other significant ocular pathology, such as anatomical abnormalities that increase the risk for RVO.
* Patients with a history of corneal erosion (instability of corneal epithelium), corneal degeneration, active or recurrent keratitis, and other forms of serious ocular surface inflammatory conditions.
* History of rhabdomyolysis.
* Patients with a history of hypersensitivity to any of the active (Avutometinib, defactinib) or inactive (hydroxypropylmethylcellulose, mannitol, magnesium stearate) ingredients of the investigational product.
* Female patients who are breastfeeding.
* Any other medical condition (e.g., cardiac, gastrointestinal, pulmonary, psychiatric, neurological, genetic, etc.) that in the opinion of the Investigator would places the patient at unacceptably high risk for toxicity.
* Exposure to medications (with or without prescriptions), supplements, herbal remedies, or foods with potential for drug-drug interactions with study interventions within 14 days prior to the first dose of study intervention and during the course of therapy (Appendix 1), including:

  * strong CYP3A4 inhibitors or inducers, due to potential drug-drug interactions with both Avutometinib and defactinib.
  * strong CYP2C9 inhibitors or inducers, due to potential drug-drug interactions with defactinib.
  * P-glycoprotein (P-gp) inhibitors or inducers, due to potential drug-drug interactions with defactinib.

---

## üìä TRIAL DESCRIPTION

The researchers are doing this study to find out whether the combination of avutometinib, defactinib, and letrozole is an effective treatment for people with low-grade serous ovarian cancer (LGSOC). The researchers will also look at the safety of this combination.

---

## üè• LOCATION DETAILS

### NYC Metro Locations (Priority for Ayesha)

1. **Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)** - Basking Ridge, New Jersey
2. **Memorial Sloan Kettering Monmouth (Limited Protocol Activities)** - Middletown, New Jersey
3. **Memorial Sloan Kettering Bergen (Limited Protocol Activities)** - Montvale, New Jersey
4. **Memorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities)** - Commack, New York
5. **Memorial Sloan Kettering Westchester (Limited Protocol Activities)** - Harrison, New York
6. **Memorial Sloan Kettering Cancer Center** - New York, New York
7. **Memorial Sloan Kettering Nassau (Limited Protocol Activities)** - Uniondale, New York

---

## ‚ö†Ô∏è CRITICAL GATES FOR AYESHA

‚úÖ No critical biomarker gates identified. Proceed with standard eligibility screening.

---

## ‚öîÔ∏è TACTICAL RECOMMENDATIONS

**Priority**: üî• **P0 - IMMEDIATE ACTION** (Eligibility: ~100%)

**Next Steps**:
1. **Order biomarker tests** (HER2 IHC, HRD if not done)
2. **Contact trial site** (within 48 hours)
3. **Pre-screen Ayesha** (get on coordinator's radar)
4. **Decision at Week 2**: Enroll if eligible
5. **Prepare medical records** (surgical report, pathology, CA-125 history)

**Expected Timeline**:
- Week 1: Complete L1 chemo (cycle 6)
- Week 2: Biomarker results available
- Week 3: Enroll in trial (if eligible) or proceed with SOC maintenance


---

## üéØ VALUE PROPOSITION

**WIN-WIN SCENARIO**:
- If eligible (100% chance) ‚Üí Access to experimental therapy
- If not eligible ‚Üí Gets proven SOC (PARP or bevacizumab maintenance)
- Either way, Ayesha receives appropriate care

**Risk-Benefit**: Low risk (pre-screening doesn't commit to enrollment), high reward (cutting-edge therapy)

---

## üìä PROVENANCE

**Generated By**: Zo (Lead Commander)  
**Pipeline Version**: v2.0 (Modular)  
**Data Source**: AstraDB vector search + Multi-stage filtering  
**Semantic Match Score**: 0.000  
**Composite Score**: 0.97 (Stage 1: 0.90, Stage 2: 0.95, Stage 3: 1.00, Stage 4: 1.00)  
**LLM Analysis**: Gemini gemini-2.5-pro  
**Quality**: ‚úÖ COMMANDER-GRADE INTELLIGENCE (Modular Pipeline v2.0)

---

**RESEARCH USE ONLY (RUO)** - This intelligence report is for research and strategic planning. All enrollment decisions must be reviewed by Ayesha's oncologist.

---

**‚öîÔ∏è FOR AYESHA!** ‚öîÔ∏è
